Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.70 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.67 |
| ▸ | RAD52 | P43351 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608009 | 1.00 | FPR2 (0.70) | FPR2SLC6A1RAD52LMNAMAPT | |
| Hydrochloric Acid SCHEMBL8195173 | 0.99 | FPR2 (0.69) | FPR2SLC6A1RAD52LMNAMAPT | |
| Hydrochloric Acid SCHEMBL8195170 | 0.99 | FPR2 (0.69) | FPR2SLC6A1RAD52LMNAMAPT | |
| SCHEMBL9083831 | 0.92 | SLC6A1 (0.81) | FPR2SLC6A1 | |
| SCHEMBL9085197 | 0.92 | SLC6A1 (0.81) | FPR2SLC6A1 | |
| Hydrochloric Acid SCHEMBL8859077 | 0.91 | SLC6A1 (0.79) | FPR2SLC6A1 | |
| Hydrochloric Acid SCHEMBL8859068 | 0.91 | SLC6A1 (0.79) | FPR2SLC6A1 | |
| SCHEMBL7607235 | 0.89 | SLC6A1 (0.82) | SLC6A1DRD2HRH1 | |
| SCHEMBL7607241 | 0.89 | SLC6A1 (0.82) | SLC6A1DRD2HRH1 | |
| Hydrochloric Acid SCHEMBL8195734 | 0.88 | SLC6A1 (0.80) | SLC6A1DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0738262-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2000-04-19 | — | — | EP | claimed |
| US-6043239-A | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF THE N-SUBSTITUENT; TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS | NOVO NORDISK A/S (DK) | 2000-03-28 | — | — | US | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-5741791-A | ADMINISTERING COMPOUNDS WHICH INHIBIT SECRETION, CIRCULATION OR EFFECT OF INSULIN ANTAGONIZING PEPTIDES; CAN BE USED TO TREAT NON-INSULIN-DEPENDENT DIABETES MELLITUS | NOVO NORDISK A/S (DK) | 1998-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | FPR2 843/4885SLC6A1 3399/4885RAD52 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.